Fisetin to Reduce Senescence and Mobility Impairment in PAD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Fisetin to Reduce Senescence and Mobility Impairment in PAD — Stella

Home/Peripheral Arterial Disease/

View on ClinicalTrials.gov

Recruiting

Back to Peripheral Arterial Disease trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Northwestern University Feinberg School of Medicine, Chicago, Illinois

Key details

Phase

Safety & dosing

Sponsor

Northwestern University

Enrollment target

~34 participants

Started

September 2024

Primary completion

November 2026

Age range

50 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.